<DOC>
	<DOC>NCT01454115</DOC>
	<brief_summary>The primary objective is to assess the safety and tolerability of a single oral dose of BMS-708163 in healthy young male subjects and in elderly male and female subjects.</brief_summary>
	<brief_title>Study to Evaluate the Safety, Pharmacokinetics and Tolerability of BMS-708163</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Panels 1 8 and Panels 1415: healthy male subjects between the ages of 18 to 45 Panels 9 and 10: healthy elderly males and females ages 60 and greater Panel 11: healthy males between the ages of 4659 Panel 12: males and/or females either healthy or with mild cognitive impairment (MCI) between the ages of 60 and 74 Panel 13: males and/or females, healthy or with Alzheimer's disease (AD) or MCI that were 75 years of age or greater Acceptable medical history, physical examinations, vital signs, electrocardiograms, hemoccult stool tests, and clinical laboratory evaluations</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
</DOC>